NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch  1  2  3  4  5  » 
found files: 574
AstraZeneca »17/02/2007 [Company watch]
AstraZeneca Wins 2nd Award for Investment in China

Following $134millions investment in a manufacturing plant at Wuxi in 2001, AZ have announced a further $35millions investment in the site. In May 2006 AZ announced its intention to invest $100millions in R & D in China....   more»

Novartis »11/02/2007 [Company watch]
Novartis to focus on Hepatitus drugs in China

Novartis will launch a product for hepatitus B this year as it is China\\\'s prevalent disease with approx 20 million affected. CEO Vasella says they have been growing by 20% on average over the last 5 years and gained considerable market share....   more»

Novo Nordisk »05/03/2007 [Company watch]
Novo Nordisk and Chinese Academy of Science establish Research Foundation

Novo Nordisk have committed $2million to co-fund research activities of mutual interest - diabetes and biopharmaceuticals....   more»

Charles River »23/03/2007 [Company watch]
Charles River commits to large expansion programme in Shanghai

Charles River Laboratories International, Inc. (NYSE:CRL) announced today the expansion of its global footprint in Asia as part of its strategy to support customers' research and development efforts in this rapidly growing market....   more»

AstraZeneca »23/03/2007 [Company watch]
AStraZeneca name site for lab expansion plan

AStrazeneca confirm site for their $100Million R & D expansion in China as the Zhangjiang Hi-Tech park in Shanghai with completion due in mid 2007. Recruitrment of scientists is already underway. The Innovation Center China will open in mid-2007 before the establishment of a permanent site that officials are still looking for....   more»

TAKEDA Pharmaceutical Company »01/04/2007 [Company watch]
China Biopharma forms distribution agreement with Takeda

China biopharma announced today that its Chinese subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd., has entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd. ("Takeda"), the largest pharmaceutical company in Japan. As part of Takeda's goal to expand sales channels in Asia, China Biopharma has begun distributing Serrapeptase tablets, and the agreement with Takeda calls for China Biopharma to distribute additional drugs as they become available....   more»

Wyeth »01/04/2007 [Company watch]
Wyeth considering relocation from China to India

Exasperated by the slow pace of regulatory procedures in China for the approval of new drugs, American pharmaceutical and healthcare giant Wyeth is believed to be exploring the option of relocating its Asian drugs research operations from China to India. Sherry Ku, Wyeth’s senior director in China, has been quoted in the local media as saying on the sidelines of a pharmaceutical conference in Hainan province that, while there was, as of now, no timetable for shifting to India, such a move was possible, even inevitable, if the regulatory environment in mainland China did not improve....   more»

»02/03/2007 [Company watch]
AXM Pharma acquires Chinese Research Institute

Shenyang based AXM Pharma, a manufacturer of proprietry and generic pharmaceutical products for China and other Asian markets will acquire Beijing Yuhuatang Biological Sci-Tech Development, a leading chinese research institute...   more»

»03/04/2007 [Company watch]
3SBio Inc. Announces Fourth Quarter And Fiscal Year 2006 Results

Total net revenues increased 25.3% to RMB127.8 million (US$16.4 million). Research and development expenses: increased 90.9% to RMB6.1 million (US$0.8 million) for 2006 from RMB3.2 million for 2005....   more»

»11/04/2007 [Company watch]
Benda Pharmaceutical, Inc. acquired 57.57% of Shenzhen SiBiono GeneTech Co., Ltd. ("SiBiono"), maker of Gendicine® cancer commercialized gene therapy product.

Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company engaged in the identification, discovery, development, and manufacturing of conventional medicines, active pharmaceutical ingredients and pharmaceutical intermediaries (or bulk chemicals), and Traditional Chinese Medicines, announced today that, through its 95% owned China-based subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co., Ltd. ("Benda Ebei"), it has treatment, the world's first approved and acquired 57.57% of Shenzhen SiBiono GeneTech Co., Ltd. ("SiBiono"), maker of Gendicine® cancer commercialized gene therapy product....   more»

AstraZeneca »24/04/2007 [Company watch]
AStra Zeneca are advertising for :TRANSLATIONAL SCIENTIST for pre-clinical development in cancer research

AStra Zeneca are seeking an experienced scientist to lead pre clinical cancer trials team in the Shanghai Innovation Centre - full job advert below, to be fully operational by 2009...   more»

Novo Nordisk »03/05/2007 [Company watch]
Novo Nordisk will continue to exploit the emerging importance of China in pharma research by establishing a new diabetes research foundation there.

UPDATE: The Danish pharma company is setting up a joint science research foundation with the Chinese Academy of Science (CAS). The collaboration will concentrate on diabetes and biopharmaceuticals research, including related fields and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology and drug delivery....   more»

3SBIO (Shenyang Sunshine) »03/05/2007 [Company watch]
3SBio Inc. Announces First Quarter 2007 Results

this company is getting a lot of attention - sells products similar to Amgen but without the side effects. Very large growth potential...   more»

Johnson & Johnson »15/04/2007 [Company watch]
Johnson & Johnson Buys China’s Dabao

China ’s largest cosmetic manufacturer, Dabao, has reportedly been bought by Johnson and Johnson (J&J) for 2.3 billion Yuan (approximately US$299 million)....   more»

Shanghai ChemPartner Co.,Ltd. »25/04/2007 [Company watch]
Biotage, Chempartner sign multi-instrument deal

Shanghai Chempartner Co., Ltd., one of China’s leading contract research organizations (CRO), has invested in Biotage SP automated flash instruments and Initiator microwave synthesizers with delivery scheduled over the next 12 months. This is Biotage's largest single order in China at a value of $1.48 m....   more»

GlaxoSmithKline »03/05/2007 [Company watch]
China recognises GSK for busting fake drugs racket

Undercover agents employed by GlaxoSmithKline (GSK) posed as traders in fake medicines to help to close down a global pharmaceutical counterfeiting racket based in China...   more»

Covance »30/04/2007 [Company watch]
First Quarter 07 Results

copy of results...   more»

Charles River »08/05/2007 [Company watch]
Charles River announces 1st Quarter 2007 results

see full report...   more»

Charles River »24/04/2007 [Company watch]
Charles River Laboratories Appoints Cheri Walker, Ph.D. as Corporate Senior Vice President, Corporate Development

Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr. Walker will be responsible for the Company's global corporate development function, directing all aspects of our merger, acquisition and strategic joint venture activities. She will also participate as an integral member in the strategic planning process of the Company. Prior to joining Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for QIAGEN Sciences where she oversaw the corporate development of QIAGEN's North American life sciences tools and molecular diagnostics businesses. Previously, Dr. Walker held senior corporate development and operational positions at Invitrogen where she successfully executed acquisition and licensing transactions. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories noted, "We are delighted to have Cheri join the Charles River team. Her depth of experience in life science transactions adds greater strength to our management team." Dr. Walker commented, "I have followed the growth of Charles River for several years and am very excited to be joining a dynamic and expanding company. Corporate Development will play an integral role in this growth and I am looking forward to being part of the team." Dr. Walker holds a doctorate in Human and Molecular Genetics from Baylor College of Medicine and a bachelor's degree in Biology from Swarthmore College....   more»

Novartis »23/04/2007 [Company watch]
Novartis with dynamic growth in the 2007 first quarter

Strong 2007 first quarter performance as Group net sales advance 18% (+15% in local currencies) to USD 9.8 billion on excellent performances from all divisions Group continuing operations operating income up 18%, net income up 17%...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.